Figure 1 from Liquid and Tissue Biopsies for Identifying MET Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib

Patient prescreening/screening and enrollment. *One (0.3%) patient was enrolled based on local testing in a protocol violation. LBx-negative, negative for METex14 skipping in LBx; LBx-positive, positive for METex14 skipping in LBx; LBxN/A<...

Повний опис

Збережено в:

Бібліографічні деталі
Автор:	Christian Rolfo (17314293) (author)
Інші автори:	Aurora O’Brate (21632380) (author), Christoph Menzel (21632383) (author), Rolf Bruns (15331351) (author), Dilafruz Juraeva (21468025) (author), Christopher Stroh (16494599) (author), Andreas Johne (15331354) (author), Paul K. Paik (15055771) (author)
Опубліковано:	2025
Предмети:	Cancer Cancer Detection and Diagnosis Therapeutic Research and Development Clinical Research and Trials Methods and Technology Biomarkers Clinical Trial Results Phase II clinical trials Liquid Biopsy Lung Cancer Small Molecule Agents
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

Figure 1 from Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib

Схожі ресурси